SSC 2016

1. SURVIVING SEPSIS COMPAIGN
International Guidelines for Management
of Sepsis and Septic Shock
2016
Dr KRUNAL BHATT
ANAESTHESIOLOGY AND CRITICAL CARE
AFMC , PUNE

2. • First Publication : 2004
• Followed by : 2008 , 2012 , 2016

3. CONCERNS
• Initial resuscitation
• Screening for sepsis and performance improvement
• Diagnosis
• Antimicrobial Therapy
• Source Control
• Fluid Therapy
• Vasoactive Medications
• Corticosteroids
• Blood Products
• Immunoglobulins

4. CONCERNS
• Blood Purification
• Anticoagulants
• Mechanical Ventilation
• Sedation Analgesia
• Glucose Control
• RRT
• Bicarbonate Therapy
• VTE Prophylaxis
• Stress Ulcer Prophylaxis
• Nutrition
• Setting Goals of Care

5. INITIAL RESUSCITATION
• Sepsis and septic shock are medical emergencies, treatment
and resuscitation begin immediately (BPS)
• In the resuscitation from sepsis-induced hypo perfusion, at
least 30 mL/kg of IV crystalloid fluid be given within the first 3
hours ( Strong R, Low QOE )

6. INITIAL RESUSCITATION
• Following initial fluid resuscitation, additional fluids be guided
by frequent reassessment of hemodynamic status (BPS)
Reassessment should include a thorough clinical examination and evaluation of
available physiologic variables ( HR, BP , arterial oxygen saturation, RR , T , urine
output, and others, as available) as well as other noninvasive or invasive
monitoring, as available
• Further hemodynamic assessment (such as assessing cardiac
function) to determine the type of shock if the clinical
examination does not lead to a clear diagnosis (BPS)

7. INITIAL RESUSCITATION
• Dynamic over static variables be used to predict fluid
responsiveness, where available ( Weak R, Low QOE )
• Initial target MAP of 65 mm Hg in patients with septic shock
requiring vasopressors ( Strong R, Mod QOE)
• Guiding resuscitation to normalize lactate in patients with
elevated lactate levels as a marker of tissue hypo perfusion
. ( Weak R, Low QOE )

8. SCREENING FOR SEPSIS AND
PERFORMANCE IMPROVEMENT
• Hospitals and hospital systems have a performance
improvement program for sepsis, including sepsis screening
for acutely ill, high risk patients (BPS)

9. DIAGNOSIS
• Appropriate routine microbiologic cultures (including blood)
be obtained before starting antimicrobial therapy in patients
with suspected sepsis or septic shock if doing so results in no
substantial delay in the start of antimicrobials (BPS)
Appropriate routine microbiologic cultures always include at least two sets of
blood cultures (aerobic and anaerobic)

10. ANTIMICROBIAL THERAPY
• Administration of IV antimicrobials should be initiated as soon
as possible after recognition and within one hour for both
sepsis and septic shock ( Strong R, Mod QOE)
• Empiric broad-spectrum therapy with one or more
antimicrobials for patients presenting with sepsis or septic
shock to cover all likely pathogens (including bacterial and
potentially fungal or viral coverage) ( Strong R, Mod QOE)

11. ANTIMICROBIAL THERAPY
• Empiric antimicrobial therapy be narrowed once pathogen
identification and sensitivities are established and/or
adequate clinical improvement is noted (BPS)
• Against sustained systemic antimicrobial prophylaxis in
patients with severe inflammatory states of noninfectious
origin (e.g., severe pancreas, burn injury) (BPS)

12. ANTIMICROBIAL THERAPY
• Dosing strategies of antimicrobials be optimized based on
accepted pharmaco kinetic / pharmaco dynamic principles
and specific drug properties in patients with sepsis or
septic shock (BPS)
• Empiric combination therapy (using at least two antibiotics of
different antimicrobial classes) aimed at the most likely
bacterial pathogen(s) for the initial management of septic
shock ( Weak R, Low QOE )

14. ANTIMICROBIAL THERAPY
• Combination therapy not be routinely used for ongoing
treatment of most other serious infections, including
bacteremia and sepsis without shock ( Weak R, Low QOE )
This does not preclude the use of multidrug therapy to broaden antimicrobial
activity
• Against combination therapy for the routine treatment of
neutropenic sepsis / bacteremia ( Strong R, Mod QOE )
This does not preclude the use of multidrug therapy to broaden antimicrobial
activity

15. ANTIMICROBIAL THERAPY
• If combination therapy is used for septic shock, de-escalation
with discontinuation of combination therapy within the first
few days in response to clinical improvement and/or evidence
of infection resolution. This applies to both targeted (for
culture-positive infections) and empiric (for culture-negative
infections) combination therapy (BPS)
• Antimicrobial treatment duration of 7 to 10 days is adequate
for most serious infections associated with sepsis and septic
shock ( Weak R, Low QOE )

16. ANTIMICROBIAL THERAPY
• Longer courses are appropriate in patients who have a slow
clinical response, undrainable foci of infection, bacteremia
with Staphylococcus aureus, some fungal and viral infections,
or immunologic deficiencies, including neutropenia
( Weak R, Low QOE )
• Shorter courses are appropriate in some patients, particularly
those with rapid clinical resolution following effective source
control of intra-abdominal or urinary sepsis and those with
anatomically uncomplicated pyelonephritis
( Weak R, Low QOE )

17. ANTIMICROBIAL THERAPY
• Daily assessment for de-escalation of antimicrobial therapy in
patients with sepsis and septic shock (BPS)
• Measurement of procalcitonin levels can be used to support
shortening the duration of antimicrobial therapy in sepsis
patients ( Weak R, Low QOE )
• Procalcitonin levels can be used to support the
discontinuation of empiric antibiotics in patients who initially
appeared to have sepsis, but subsequently have limited
clinical evidence of infection ( Weak R, Low QOE )

18. SOURCE CONTROL
• Specific anatomic diagnosis of infection requiring emergent
source control should be identified or excluded as rapidly as
possible in patients with sepsis or septic shock, and that any
required source control intervention should be implemented
as soon as medically and logistically practical after the
diagnosis is made (BPS)
• Prompt removal of intravascular access devices that are a
possible source of sepsis or septic shock after other vascular
access has been established (BPS)

19. FLUID THERAPY
• Fluid challenge technique be applied where fluid
administration is continued as long as hemodynamic factors
continue to improve (BPS)
• Crystalloids as the fluid of choice for initial resuscitation and
subsequent intravascular volume replacement in patients
with sepsis and septic shock ( Strong R, Mod QOE)
• Using either balanced crystalloids or saline for fluid
resuscitation of patients with sepsis or septic shock
( Weak R, Low QOE )

20. FLUID THERAPY
• Using albumin in addition to crystalloids for initial
resuscitation and subsequent intravascular volume
replacement in patients with sepsis and septic shock, when
patients require substantial amounts of crystalloids
( Weak R, Low QOE )
• Against using hydroxyethyl starches for intravascular volume
replacement in patients with sepsis or septic shock
( Strong R, High QOE )

21. FLUID THERAPY
• Using crystalloids over gelatins when resuscitating patients
with sepsis or septic shock ( Weak R, Low QOE )

22. VASOACTIVE MEDICATIONS
• Norepinephrine as the first-choice vasopressor
( Strong R , Mod QOE )
• Adding either vasopressin (up to 0.03 U/min) ( Weak R , Mod
QOE ) or
Epinephrine ( Weak R , Low QOE ) to norepinephrine with the
intent of raising MAP to target, or
adding vasopressin (up to 0.03 U/min) ( Weak R , Mod QOA )
to decrease norepinephrine dosage

23. VASOACTIVE MEDICATIONS
• Using dopamine as an alternative vasopressor agent to
norepinephrine only in highly selected patients (e.g., patients
with low risk of tachyarrhythmias and absolute or relative
bradycardia) ( Weak R, Low QOE )
• Against using low-dose dopamine for renal protection
( Strong R , High QOE )

24. VASOACTIVE MEDICATIONS
• Using dobutamine in patients who show evidence of
persistent hypoperfusion despite adequate fluid loading and
the use of vasopressor agents ( Weak R , Low QOE )
If initiated, dosing should be titrated to an end point reflecting perfusion, and the
agent reduced or discontinued in the face of worsening hypotension or
arrhythmias
• All patients requiring vasopressors have an arterial catheter
placed as soon as practical if resources are available
( Weak R , Low QOE )

25. CORTICOSTEROIDS
• Against using IV hydrocortisone to treat septic shock patients
if adequate fluid resuscitation and vasopressor therapy are
able to restore hemodynamic stability. If this is not achievable,
we suggest IV hydrocortisone at a dose of 200 mg per day
( Weak R , Low QOE )

26. BLOOD PRODUCTS
• RBC transfusion occur only when hemoglobin concentration
decreases to < 7.0 g/dL in adults in the absence of
extenuating circumstances, such as myocardial ischemia,
severe hypoxemia, acute hemorrhage ( Strong R , High QOE )

27. BLOOD PRODUCTS
• Against the use of erythropoietin for treatment of anemia
associated with sepsis ( Strong R , Mod QOE )
• Against the use of FFP to correct cloting abnormalities in the
absence of bleeding or planned invasive procedures
( Weak R , Very Low QOE )

28. BLOOD PRODUCTS
• Prophylactic platelet transfusion when counts are <
10,000/mm3 in absence of apparent bleeding and when
counts are < 20,000/mm3 if the patient has significant risk of
bleeding. Higher platelet counts ( ≥ 50,000/mm3) are advised
for active bleeding, surgery, or invasive procedures
( Weak R , Very low QOE )

29. IMMUNOGLOBULINS
• Against the use of IV immunoglobulins in patients with sepsis
or septic shock ( Weak R , Low QOE )

30. BLOOD PURIFICATION
• No recommendation regarding the use of blood purification

31. ANTICOAGULANTS
• Against the use of antithrombin for the treatment of sepsis
and septic shock ( Strong R , Mod QOE )
• No recommendation regarding the use of thrombomodulin or
heparin for the treatment of sepsis or septic shock

32. MECHANICAL VENTILATION
• Using a target TV of 6 mL/kg PBW compared with 12 mL/kg in
adult patients with sepsis-induced ARDS
( Strong R , High QOE )
• Using an upper limit goal for plateau pressures of 30 cm H2O
over higher plateau pressures in adult patients with sepsis-
induced severe ARDS ( Strong R , Mod QOE )
• Using higher PEEP over lower PEEP in adult patients with
sepsis-induced mod to severe ARDS ( Weak R , Mod QOE )

33. MECHANICAL VENTILATION
• Using recruitment maneuvers in adult patients with sepsis-
induced, severe ARDS ( Weak R , Mod QOE )
• Using prone over supine position in adult patients with sepsis-
induced ARDS and a PaO2/FIO2 ratio < 150
( Strong R , Mod QOE )
• Against using HFOV in adult patients with sepsis-induced
ARDS ( Strong R , Mod QOE )

34. MECHANICAL VENTILATION
• No recommendation regarding the use of NIV for patients
with sepsis-induced ARDS
• Using NMB agents for 48 hours in adult patients with sepsis-
induced ARDS and a PaO2/FIO2 ratio < 150 mm Hg
( Weak R , Mod QOE )
• Conservative fluid strategy for patients with established
sepsis-induced ARDS who don’t have evidence of tissue
hypoperfusion ( Strong R , Mod QOE )

35. MECHANICAL VENTILATION
• Against the use of ß-2 agonists for the treatment of patients
with sepsis-induced ARDS without bronchospasm
( Strong R , Mod QOE )
• Against the routine use of the pulmonary artery catheter for
patients with sepsis-induced ARDS ( Strong R , High QOE )
• Using lower TVs over higher TVs in adult patients with sepsis-
induced respiratory failure without ARDS( Weak R , Low QOE )

36. MECHANICAL VENTILATION
• Mechanically ventilated sepsis patients be maintained with
the head of the bed elevated between 30 and 45 degrees to
limit aspiration risk and to prevent the development of VAP
( Strong R , Low QOE )
• Using SBTs in mechanically ventilated patients with sepsis
who are ready for weaning ( Strong R , High QOE )
• Using a weaning protocol in mechanically ventilated patients
with sepsis-induced respiratory failure who can tolerate
weaning ( Strong R , Mod QOE )

37. SEDATION AND ANALGESIA
• Continuous or intermittent sedation be minimized in
mechanically ventilated sepsis patients, targeting specific
titration end points (BPS)

38. GLUCOSE CONTROL
• Protocolized approach to blood glucose management in ICU
patients with sepsis, commencing insulin dosing when two
consecutive blood glucose levels are > 180 mg/dL. This
approach should target an upper blood glucose level ≤ 180
mg/dL rather than an upper target blood glucose level ≤ 110
mg/dL ( Strong R , High QOE )
• Blood glucose values be monitored every 1 to 2 hours until
glucose values and insulin infusion rates are stable, then every
4 hours thereafter in patients receiving insulin infusions (BPS)

39. GLUCOSE CONTROL
• Glucose levels obtained with point-of-care testing of capillary
blood be interpreted with caution because such
measurements may not accurately estimate arterial blood or
plasma glucose values (BPS)
• Use of arterial blood rather than capillary blood for point-of-
care testing using glucose meters if patients have arterial
catheters ( Weak R , Low QOE )

40. RRT
• Either continuous or intermittent RRT be used in patients with
sepsis and AKI ( Weak R , Mod QOE )
• Using continuous therapies to facilitate management of fluid
balance in hemodynamically unstable septic patients
( Weak R , Very Low QOE )
• Against the use of RRT in patients with sepsis and AKI for
increase in creatinine or oliguria without other definitive
indications for dialysis ( Weak R , Low QOE )

41. BICARBONATE THERAPY
• Against the use of sodium bicarbonate therapy to improve
hemodynamics or to reduce vasopressor requirements in
patients with hypo perfusion-induced lactic acidemia with pH
≥7.15 ( weak R , mod QOE )

42. VTE PROPHYLAXIS
• Pharmacologic prophylaxis ( UFH or LMWH ) against VTE in
the absence of contraindications to the use of these agents
( Strong R , Mod QOE )
• LMWH rather than UFH for VTE prophylaxis in the absence of
contraindications to the use of LMWH ( Strong R , Mod QOE )
• Combination pharmacologic VTE prophylaxis and mechanical
prophylaxis, whenever possible ( Weak R , Low QOE )

43. VTE PROPHYLAXIS
• Mechanical VTE prophylaxis when pharmacologic VTE is
contraindicated ( Weak R , Low QOE )

44. STRESS ULCER PROPHYLAXIS
• Stress ulcer prophylaxis be given to patients with sepsis or
septic shock who have risk factors for GI bleeding
( Strong R , Low QOE )
• Using either PPIs or H-2 receptor antagonists when stress
ulcer prophylaxis is indicated ( Weak R , Low QOE )
• Against stress ulcer prophylaxis in patients without risk factors
for GI bleeding (BPS)

45. NUTRITION
• Against the administration of early parenteral nutrition alone
or parenteral nutrition in combination with enteral feedings
(but rather initiate early enteral nutrition) in critically ill
patients with sepsis or septic shock who can be fed enterally
( Strong R , Mod QOE )
• Against the administration of parenteral nutrition alone or in
combination with enteral feeds (but rather to intiate IV
glucose and advance enteral feeds as tolerated) over first 7
days in critically ill patients with sepsis/septic shock for whom
early enteral feeding is nt feasible ( Strong R , Mod QOE )

46. NUTRITION
• Early initiation of enteral feeding rather than a complete fast
or only IV glucose in critically ill patients with sepsis or septic
shock who can be fed enterally ( Weak R , Low QOE )
• Either early trophic / hypocaloric or early full enteral feeding
in critically ill patients with sepsis or septic shock; if trophic /
hypocaloric feeding is the initial strategy, then feeds should be
advanced according to patient tolerance
( Weak R , Mod QOE )

47. NUTRITION
• Against the use of omega-3 fatty acids as an immune
supplement in critically ill patients with sepsis or septic shock
( Strong R , Low QOE )
• Against routinely monitoring gastric residual volumes in
critically ill patients with sepsis or septic shock
( Weak R , Low QOE )
However, measurement of gastric residuals in patients with
feeding intolerance or who are considered to be at high risk of
aspiration ( Weak R , Very low QOE )
This recommendation refers to nonsurgical critically ill patients with sepsis or
septic shock

48. NUTRITION
• Use of prokinetic agents in critically ill patients with sepsis or
septic shock and feeding intolerance ( Weak R , Low QOE )
• Placement of post-pyloric feeding tubes in critically ill patients
with sepsis or septic shock with feeding intolerance or who are
considered to be at high risk of aspiration
( Weak R , Low QOE )
• Against the use of IV selenium to treat sepsis and septic shock
( Strong R , Mod QOE )

49. NUTRITION
• Against the use of arginine to treat sepsis and septic shock
( Weak R , Low QOE )
• Against the use of glutamine to treat sepsis and septic shock
( Weak R , Low QOE )
• No recommendation about the use of carnitine for sepsis and
septic shock

50. SETTING GOALS OF CARE
• Goals of care and prognosis be discussed with patients and
families (BPS)
• Goals of care be incorporated into treatment and end-of-life
care planning, utilizing palliative care principles where
appropriate ( Strong R , Mod QOE )
• Goals of care be addressed as early as feasible, but no later
than within 72 hours of ICU admission
( Weak R , Low QOE )

51. 2018 UPDTE
Hour-1 Surviving Sepsis Campaign Bundle of Care
• Measure lactate level : Remeasure if initial lactate is >
2mmol/L ( Weak R, Low QOE )
• Obtain blood culture prior to administration of antibiotics
( BPS )
• Administer broad spectrum antibiotics ( Strong R, Mod QOE )
• Begin rapid administration of 30ml/kg crystalloid for
hypotension or lactate ≥4mmol/L ( Strong R, Low QOE )
• Apply vasopressors if patient is hypotensive during or after
fluid resuscitation to maintain MAP ≥ 65 mmHg
( Strong R, Mod QOE )

52. 2018 UPDTE
• Consistent with previous iterations of the SSC sepsis bundles,
“time zero” or “time of presentation”
is defined as the time of triage in the emergency department
or, if referred from another care location, from the earliest
chart annotation consistent with all elements of sepsis
(formerly severe sepsis) or septic shock ascertained through
chart review

53. 2018 UPDTE
• The most important change in the revision of the SSC bundles
is that the 3-h and 6-h bundles have been combined into a
single “hour-1 bundle” with the explicit intention of beginning
resuscitation and management immediately

54. THANK YOU
DR KRUNAL BHATT